I'm LongbridgeAI, I can summarize articles.Eupraxia Pharmaceuticals reported that EP-104GI maintained remission in 64% of eosinophilic esophagitis patients at 52 weeks in the RESOLVE trial. The data showed sustained symptom relief and tissue improvement with a supportive safety profile, including no treatment-related serious adverse events. A separate Phase 2b study is currently recruiting, with interim results expected in December 2026.
- Eupraxia Pharmaceuticals released new long-term results from its Phase 1b/2a RESOLVE trial of EP-104GI in eosinophilic esophagitis. * Data were presented as an update now, showing symptom relief that generally held up for up to a year in higher-dose cohorts. * Patients also showed tissue-level improvement consistent with earlier readouts, supporting the case for a long-acting, locally delivered steroid approach. * Safety remained supportive, with no treatment-related serious adverse events reported to date in the open-label study. * A separate randomized Phase 2b RESOLVE study is recruiting; interim results are expected in December 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eupraxia Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300800PRIMZONECNPR____9836563) on September 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)